Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside

1. Analyst maintains Overweight rating with a $102 price target for Ultragenyx. 2. Confidence in setrusumab's Phase 3 trial success supports stock valuation upside. 3. Preliminary 2024 revenue estimates exceed consensus, indicating strong financial outlook. 4. Potential Priority Review Voucher may provide non-dilutive capital opportunities. 5. Stock rose 4.31% to $41.75, reflecting positive market sentiment.